FDG PET imaging in patients with pathologically verified dementia.

UNLABELLED The purpose of this study was to confirm with pathologic verification 2 beliefs related to Alzheimer's disease (AD): (a) the long-standing impression that bilateral temporo-parietal hypometabolism, as noted on FDG PET imaging, is the metabolic abnormality associated with Alzheimer's disease (AD) and (b) that the sensitivity, specificity, and diagnostic accuracy of the metabolic pattern of bilateral temporo-parietal hypometabolism allows differentiation between other degenerative causes of dementia. METHODS Twenty two individuals (8 women, 14 men) with difficult-to-characterize memory loss or dementia (using standard clinical criteria), and who eventually received pathologic confirmation of diagnosis, were evaluated. FDG PET brain scans were obtained and visually graded by an experienced nuclear medicine physician as to the presence of classic bilateral temporo-parietal hypometabolism as seen in Alzheimer's type dementia. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of the metabolic pattern of bilateral temporo-parietal hypometabolism were determined using pathologic diagnosis as the gold standard. RESULTS The clinical diagnosis of possible or probable AD was determined as the primary cause of dementia in 12 patients. The sensitivity and specificity of the clinical diagnosis for probable AD were 63% and 100%, respectively. The sensitivity and specificity of the clinical diagnosis for possible and probable AD were 75% and 100%, respectively. The sensitivity, specificity, and diagnostic accuracy of bilateral temporo-parietal hypometabolism being associated with AD were 93%, 63%, and 82%, respectively. CONCLUSION This study confirms that bilateral temporo-parietal hypometabolism is indeed the classic metabolic abnormality associated with AD. Furthermore, in individuals with dementia whose FDG PET scans indicated a metabolic pattern other than bilateral temporo-parietal hypometabolism, a cause of dementia other than AD should be suspected. These observations may be of clinical importance in differentiating dementia syndromes. The sensitivity, specificity, and diagnostic accuracy of FDG PET are acceptable as tests to be used in the evaluation of dementia and particularly to confirm the clinical suspicion of AD.

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[2]  S. Prusiner,et al.  Bitemporal hypometabolism in Creutzfeldt-Jakob disease measured by positron emission tomography with [18F]-2-fluorodeoxyglucose. , 1984, Journal of computer assisted tomography.

[3]  Arne Brun,et al.  PATHOLOGICAL AND POSITRON EMISSION TOMOGRAPHIC CORRELATIONS IN ALZHEIMER'S DISEASE , 1985, The Lancet.

[4]  V. Hachinski,et al.  A NEW DEFINITION OF ALZHEIMER'S DISEASE: A HIPPOCAMPAL DEMENTIA , 1985, The Lancet.

[5]  Z. Khachaturian Diagnosis of Alzheimer's disease. , 1985, Archives of neurology.

[6]  R Harrop,et al.  Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease , 1986, Neurology.

[7]  Peter Herscovitch,et al.  Correction of Positron Emission Tomography Data for Cerebral Atrophy , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  B. L. Beattie,et al.  Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. , 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[9]  M. Tierney,et al.  The Differential Diagnosis of Alzheimer's Disease: Conceptual and Methodological Issues , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[10]  G. V. Van Hoesen,et al.  Alzheimer's disease: Glutamate depletion in the hippocampal perforant pathway zone , 1987, Annals of neurology.

[11]  C. Filley Diagnosis of Alzheimer's disease. , 1988, Colorado medicine.

[12]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[13]  W. Snow,et al.  The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimerʼs disease: a clinicopathologic study of 57 cases , 1988 .

[14]  M Haupt,et al.  [Clinical diagnosis of Alzheimer's disease]. , 1988, Deutsche medizinische Wochenschrift.

[15]  W. Snow,et al.  The NINCDS‐ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease , 1988, Neurology.

[16]  J. Mazziotta,et al.  [18F]-fluorodeoxyglucose (FDG) and positron emission tomography (PET) in aging and dementia. A decade of studies. , 1989, European neurology.

[17]  A. Bol,et al.  Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy , 1989, Annals of neurology.

[18]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[19]  R Harrop,et al.  Correlations of regional postmortem enzyme activities with premortem local glucose metabolic rates in alzheimer's disease , 1990, Journal of neuroscience research.

[20]  S. Stein,et al.  Normal-pressure hydrocephalus. , 1974, Lancet.

[21]  B. L. Beattie,et al.  18Fluorodeoxyglucose Positron Emission Tomography Studies in Presumed Alzheimer Cases, Including 13 Serial Scans , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[22]  A. R. Damasio,et al.  Pathological alterations in the amygdala in Alzheimer's disease , 1990, Neuroscience.

[23]  Karl Herholz,et al.  Criteria for the Diagnosis of Alzheimer's Disease with Positron Emission Tomography , 1990 .

[24]  I. Mena,et al.  Temporal-parietal hypoperfusion with single-photon emission computerized tomography in conditions other than alzheimer’s disease , 1990 .

[25]  Y Agid,et al.  Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. , 1990, Archives of neurology.

[26]  F. Shishido,et al.  [Brain glucose metabolism in a patient with Creutzfeldt-Jakob disease measured by positron emission tomography]. , 1990, Kaku igaku. The Japanese journal of nuclear medicine.

[27]  Functional Brain Imaging and Alzheimer-Type Dementia , 1991, Alzheimer disease and associated disorders.

[28]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[29]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[30]  S. Rapoport,et al.  Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review. , 1991, Cerebrovascular and brain metabolism reviews.

[31]  W. Jagust,et al.  Diminished Glucose Transport in Alzheimer's Disease: Dynamic PET Studies , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  Rapoport Si,et al.  Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review. , 1991 .

[33]  T. Videen,et al.  Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease , 1992, Neurology.

[34]  Richard S. J. Frackowiak,et al.  The use of positron emission tomography in the clinical assessment of dementia. , 1992, Seminars in nuclear medicine.

[35]  N Butters,et al.  Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. , 1992, Archives of neurology.

[36]  B L Holman,et al.  The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  M J de Leon,et al.  Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. , 1992, Archives of neurology.

[38]  P. Pietrini,et al.  Early Detection of Alzheimer's Disease: A Statistical Approach Using Positron Emission Tomographic Data , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  F Fazio,et al.  Comparability of FDG PET studies in probable Alzheimer's disease. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  A. Smith,et al.  Autopsy: consent, completion and communication in Alzheimer's disease research. , 1993, Age and ageing.

[41]  W. Jagust,et al.  Single‐Photon Emission Computed Tomographic Perfusion Imaging in Autopsy‐Diagnosed Dementia , 1993 .

[42]  E. Bigio,et al.  Brain blood flow in the dementias: SPECT with histopathologic correlation. , 1993, Radiology.

[43]  M F Kijewski,et al.  Quantitative brain SPECT in Alzheimer's disease and normal aging. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  D. Brooks PET studies in progressive supranuclear palsy. , 1994, Journal of neural transmission. Supplementum.

[45]  N. Butters,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery , 1994, Neurology.

[46]  A. Smith,et al.  Negative symptoms in schizophrenia: assessment of the effect of risperidone. , 1994 .

[47]  A. Smith,et al.  The diagnosis of Alzheimer's disease: a question of image? , 1994, The Journal of clinical psychiatry.

[48]  D Comar,et al.  Differential diagnosis of Alzheimer's disease with PET. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  I. Mena,et al.  SPECT in Dementia: Clinical and Pathological Correlation , 1995, Journal of the American Geriatrics Society.

[50]  R. Koeppe,et al.  A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  D E Kuhl,et al.  Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  J. Brandt,et al.  Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging , 1996, Neurology.

[53]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[54]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[55]  A. Smith,et al.  Comparison of Pathological Diagnostic Criteria for Alzheimer Disease , 1998, Alzheimer disease and associated disorders.

[56]  J. Growdon,et al.  Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. , 1999, Journal of neuropathology and experimental neurology.

[57]  M. Ishikawa,et al.  [Normal pressure hydrocephalus]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.